Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
about
Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-AnalysisRadiotherapy and "new" drugs-new side effects?Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.Advances in epigenetic glioblastoma therapy.Antiangiogenic therapy for glioblastoma: current status and future prospects.The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaNovel therapies in glioblastoma.Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patientsThe prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Efficacy and safety of bevacizumab for the treatment of glioblastoma.Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.Bevacizumab for the treatment of glioblastoma.Combining molecular targeted agents with radiation therapy for malignant gliomasAntivascular endothelial growth factor antibody for treatment of glioblastoma multiformeCurrent concepts in clinical radiation oncology.Bevacizumab for the treatment of high-grade glioma.Antiangiogenic therapy in the management of brain tumors: a clinical overview.Therapeutic targeting of VEGF in the treatment of glioblastoma.To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.Update on bevacizumab and other angiogenesis inhibitors for brain cancer.Safety of bevacizumab in patients with malignant gliomas: a systematic review.Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.Glioblastoma multiforme: State of the art and future therapeutics.State of the art and perspectives in the treatment of glioblastoma.Novel chemotherapeutics and other therapies for treating high-grade glioma.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials.Bevacizumab as first-line therapy for glioblastoma.The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.Disseminated progression of glioblastoma after treatment with bevacizumab.Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.Contemporary management of high-grade gliomas.Decision making and management of gliomas: practical considerations.Bevacizumab therapy for glioblastoma: a passionate discussion.Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
P2860
Q26783779-77A28BB8-40E5-4CF5-A32F-463346CD4DEDQ26861498-FE905F04-B82C-44F5-8AE0-779426C9FB1BQ30417015-0A202A9A-C621-49E2-AFA9-DD51E1F37620Q30708866-A9259099-007F-4794-A4A0-701D12482362Q33414998-49C529D6-C824-4F22-9D77-83C310BBF0C1Q33567030-10EB2EAA-AF10-45AD-AF80-1BC7A468C8B1Q34523319-AF8D0ECD-3DA4-4BAF-BD0B-22438A3E2EECQ35053326-DC21589E-E5CD-41A2-AE69-4CD51FD33FFDQ35864136-BA83AF95-7C98-4A96-ABEC-22834B5B63D6Q36235176-3BD9431F-4F10-408C-A3CD-5278C4FC7E29Q36299167-279ED59F-FE1C-41A5-B18E-9D88DF0976EEQ36523864-7377BAF6-FFD1-42AF-B53D-E52BD977BA62Q36828080-6AB31E0F-5181-4B15-A8C9-0229348A0090Q36929502-714CE84F-FBF9-4FCA-A788-B5BDDF3A772EQ37099594-8BFE1205-7F88-48F1-8101-E2F18DF68244Q37372416-4A7656BF-FE6B-44E6-A90D-2BAAF9E9B7E7Q37603804-0DCCBD9D-18CA-4436-BA8D-22373768ECFBQ38015896-A818C722-2B36-43C5-ADD7-05E3CAEF1EB7Q38028766-9A1B727C-D2E1-4A16-8D2C-DBF9B9F93662Q38033241-CF6923F9-9913-42A2-8BE6-9D79EF249146Q38105006-5D511874-203F-4A75-9690-2757878F556BQ38106370-40C44EBE-D90E-48B9-8659-15455DAEC844Q38166676-CF5C963C-C1B2-450C-A5D0-0A5DA7C7B5B2Q38170398-E15FD44A-AB41-43E4-8320-F99BCB4BF984Q38198121-CEB6F3D6-0A82-4F81-8091-7EE750A6B2ABQ38225874-86EC2E2C-8A15-48F9-AFEE-15245051070DQ38233067-D2ACCA91-9671-44A7-AFDC-56338BA84D65Q38569802-199CADB1-68CA-45A2-ADB7-73524DE59748Q39022941-0EC40145-7674-46FD-8AF5-B118E975386DQ39265787-EBDC0274-2C0C-4DC6-814C-6D23129E0D29Q39339970-F1E545EA-8E3D-48E2-AE1E-A622EDD350C2Q39568969-091B9D38-4571-4D85-A90C-FCBD3C1D3144Q39636415-76DBC03C-1357-4B80-A9BE-43FF3D8F5BD6Q41475531-C6CED28F-F8C9-467D-9EA6-EE3679E4174DQ42143173-C4A1410D-709D-4805-AA04-928CB5887E46Q47781482-F5933395-8428-4F12-8BB2-A499CF046F86Q48365746-AFFFDF62-B912-4446-94B3-741D99D6551CQ48641762-40162036-02DD-4357-BB81-CA18D2D58C06Q49066603-8111AE0F-6C0A-463A-9EC5-7FB617EA6050Q55461224-53877D84-6B6B-4237-82FC-C4D452F74AB3
P2860
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Addition of bevacizumab to sta ...... nosed glioblastoma multiforme.
@en
Addition of bevacizumab to sta ...... nosed glioblastoma multiforme.
@nl
type
label
Addition of bevacizumab to sta ...... nosed glioblastoma multiforme.
@en
Addition of bevacizumab to sta ...... nosed glioblastoma multiforme.
@nl
prefLabel
Addition of bevacizumab to sta ...... nosed glioblastoma multiforme.
@en
Addition of bevacizumab to sta ...... nosed glioblastoma multiforme.
@nl
P2093
P50
P1476
Addition of bevacizumab to sta ...... nosed glioblastoma multiforme.
@en
P2093
James E Herndon
James J Vredenburgh
Jennifer Marcello
John Sampson
Katherine B Peters
Leighann Bailey
Stevie Threatt
P356
10.1016/J.IJROBP.2010.08.058
P407
P577
2010-10-30T00:00:00Z